Entasis Therapeutics introduces first-class candidates

0


WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) – Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, made several presentations today at the World. known Microbe Forum 2021, which takes place virtually from June 20 to 24 Entasis will feature 11 oral presentation posters highlighting ETX0462, a novel, premium diazabicyclooctane with antimicrobial activity against Pseudomonas aeruginosa. The presentations will also include updates on SUL-DUR, a β-lactam / β-lactamase inhibitor that is currently in a pivotal Phase 3 clinical trial for the treatment of infections caused by carbapenem resistant Acinetobacter baumannii, and ETX0282CPDP, an oral β-lactam / β-lactamase inhibitor being developed to treat multidrug-resistant Gram-negative pathogens, including those caused by extended spectrum β-lactamases (ESBLs) and carbapenem-resistant Enterobacteria (CRE).

The details of the presentations are as follows:

SUL-DUR presentations:

poster: Permeability and efflux of the outer membrane limit the antibacterial activity of sulbactam-durlobactam in. not a Acinetobacter baumannii
Session: AAR09 Pharmacological studies of test substances before NDA
Poster number: WMF21-0322

poster: Influence of susceptibility test conditions on the In vitro Vi Antibacterial Activity of Sulbactam Durlobactam
session: AAR09 Pharmacological studies of test substances before NDA
Poster number: WMF21-0325

poster: Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Areas Using a CLSI M23-A4 Study Design
session: AAR09 Pharmacological studies of test substances before NDA
Poster number: WMF21-0326

ETX0282CPDP Presentation:

poster: The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017-2019), geographically different resistant drugs Enterobacteria isolated
session: AAR08 New antimicrobial agents (in vitro and in vivo studies prior to the start of clinical therapeutic studies / pre-phase 2)
Poster number: WMF21-0290

ETX0462 presentations:

Oral presentation: The discovery of the novel diazabicyclooctane (DBO) ETX0462: A single antibacterial agent used to treat gram-negative infections, including MDR Pseudomonas aeruginosa
session: AAR107 New Agent Discovery Summary: First New Antimicrobial Agents
Date and Time: Monday, June 21, 2021, 11 a.m.-12: 30 p.m.

poster: ETX0462 inhibits penicillin binding protein 3 of Pseudomonas aeruginosa and Escherichia coli
session: AAR08 New antimicrobial agents (in-vitro and in-vivo studies prior to the start of clinical therapeutic studies / pre-phase 2)
Poster number: WMF21-0287

poster: ETX0462 is a novel PBP inhibitor with strong activity against topical, global, gram-negative, clinical isolates
session: AAR08 New antimicrobial agents (in vitro and in vivo studies prior to the start of clinical therapeutic studies / pre-phase 2)
Poster number: WMF21-0293

poster: The new, non-β-lactam PBP inhibitor ETX0462 maintains its potent antibacterial activity across isogenic panels of gram-negative resistant determinants
session: AAR08 New antimicrobial agents (in-vitro and in-vivo studies prior to the start of clinical therapeutic studies / pre-phase 2)
Poster number: WMF21-0288

poster: ETX0462, a novel non-β-lactam PBP inhibitor, is bactericidal against gram-negative pathogens with a low tendency to generate mutants
session: AAR08 New antimicrobial agents (in vitro and in vivo studies prior to the start of clinical therapeutic studies / pre-phase 2)
Poster number: WMF21-0286

poster: Assessment of the pharmacokinetics / pharmacodynamics (PK / PD) of the novel diazabicyclooctane (DBO) ETX0462 against Pseudomonas aeruginosa Infections, including MDR strains
session: AAR07 Antimicrobial Pharmacokinetics and Pharmacodynamics
Poster number: WMF21-0292

poster: The new, non-β-lactam PBP inhibitor ETX0462 has a strong activity against biothreat pathogens In vitro Vi and In vivo
session: AAR08 New antimicrobial agents (in-vitro and in-vivo studies prior to the start of clinical therapeutic studies / pre-phase 2)
Date and Time: WMF21-0312

About Entasis Therapeutics Inc.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products for the treatment of serious infections caused by multi-drug resistant Gram-negative bacteria. Entasis’ pathogen-centric design platform has spawned a pipeline of product candidates, including Acinetobacter baumannii Infections), zoliflodacin (against Neisseria gonorrhoeae Infections), ETX0282CPDP (Targeting Enterobacteria Infections) and ETX0462 (targeting Pseudomonas Infections). More information is available at www.entasistx.com.

Company contact Investor contact
Kyle Dow Bruce Mackle
Entasis therapeutics LifeSci consultant
(781) 810-0114 (929) 469-3859
[email protected]x.com [email protected]



Source link

Leave A Reply

Your email address will not be published.